Blaze Bioscience Inc. Appoints Jan Öhrström, M.D., To Its Board Of Directors

SEATTLE--(BUSINESS WIRE)--Blaze Bioscience, the Tumor Paint Company®, a biotechnology company focused on guided cancer therapy, announced today that Jan Öhrström, M.D., a biotechnology executive with over 20 years of industry experience, has been appointed to the company's Board of Directors.

Dr. Öhrström brings to the Board his expertise in developing and commercializing surgical products as well as broad entrepreneurial and operational experience.

Suggested Articles

When thinking about clinical research patient recruitment, a crucial step is building effective patient recruitment advertising campaigns.

Novavax delayed the start of a large phase 3 trial for its COVID-19 vaccine in the U.S. and Mexico, thanks to delays in scaling up manufacturing.

The decision to dump IL33r antagonist GSK3772847 follows lackluster clinical data on rival candidates against the same target.